Fig. 1
(abstract P2). JDM subject responded well to rituximab therapy who had evidence of oligoclonal B cell expansion and good B cell depletion based on the JC: KRECs ratio
Fig. 1 | Pediatric Rheumatology
(abstract P2). JDM subject responded well to rituximab therapy who had evidence of oligoclonal B cell expansion and good B cell depletion based on the JC: KRECs ratio
Pediatric Rheumatology